Search

everythinglearnresearchcommunity

for

Search:↓

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Upadacitinib improved multiple immune-related conditions in one patient.

Tocilizumab might be an effective treatment for COVID-19.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Ixekizumab has known and some unexpected side effects.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Social media can help compare the effectiveness and safety of new arthritis medications.

These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Co-trimoxazole may help treat autoimmune diseases.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

Systemic corticosteroids might help treat hair loss caused by alemtuzumab in MS patients.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Enhancing Tregs can protect against alopecia areata.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.